AnalystsInsight

Robert Burns (H.C. Wainwright): Analyst Track Record and Price‑Target Accuracy

How often Robert Burns’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 2,007 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

What changed since Oct 12

Exent re-checks this page every day. Ratings appear 30 days after they are published; live calls are in Gems.

+2 new ratings (COGT, CRDF)1 upgrade4.7★ rating (was 4.8★)

Key takeaways

  • Robert Burns ranks #580 of 1,000 analysts in Exent’s scoring (4.7★).
  • 21.0% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 106 days; 34.1% of calls were up 12 months later.
  • Most‑covered stocks: NUVB, COGT, ZYME, ORIC.
  • Free on Exent: Robert Burns’s full record, with ratings 3 days after publication.

Robert Burns’s track record at a glance

Robert Burns of H.C. Wainwright ranks #580 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 21.0% of Robert’s price targets were reached, 31.4 points below the 52.4% average across all analysts.

MetricRobert BurnsAll analysts
Price‑target hit rate21.0%52.4%
Median days to hit target106 days91 days
Calls up after 12 months34.1%64.0%
Median 12‑month return of calls−27.0%+13.4%
Hit rate, last 2 years21.7%—
Average worst drop after a call−42.3%—
Ratings in the sample2,007—
Stocks covered49—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetRobert Burns
Under 30 days18.4%
30–90 days24.7%
90–180 days28.7%
Over 180 days28.2%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Robert Burns covers most

StockRatings in the sample
NUVB23
COGT22
ZYME20
ORIC19
NRIX19
CRDF17
CGEM16
KPTI16

In the past year Robert’s ratings were 96% Buy, 3% Hold and 0% Sell.

Robert Burns’s latest ratings

DateStockActionRatingPrice target
Sep 16, 2026COGTReiterated: BuyBuy$55.00
Sep 15, 2026CRDFUpgraded: BuyBuy$9.00
Sep 9, 2026INBXReiterated: BuyBuy$245.00
Sep 8, 2026PMVPReiterated: BuyBuy$5.00
Sep 4, 2026PMVPReiterated: BuyBuy$5.00
Sep 1, 2026BLSMInitiated Coverage: BuyBuy$35.00
Aug 27, 2026RVMDReiterated: BuyBuy$280.00
Aug 26, 2026ZYMEReiterated: BuyBuy$55.00
Aug 24, 2026INBXInitiated Coverage: BuyBuy$245.00
Aug 21, 2026COGTReiterated: BuyBuy$55.00
Aug 21, 2026RLAYReiterated: BuyBuy$29.00
Aug 21, 2026ELTXReiterated: BuyBuy$23.00
  • Sep 16, 2026
    Stock
    COGT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $55.00
  • Sep 15, 2026
    Stock
    CRDF
    Action
    Upgraded: Buy
    Rating
    Buy
    Price target
    $9.00
  • Sep 9, 2026
    Stock
    INBX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $245.00
  • Sep 8, 2026
    Stock
    PMVP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $5.00
  • Sep 4, 2026
    Stock
    PMVP
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $5.00
  • Sep 1, 2026
    Stock
    BLSM
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $35.00
  • Aug 27, 2026
    Stock
    RVMD
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $280.00
  • Aug 26, 2026
    Stock
    ZYME
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $55.00
  • Aug 24, 2026
    Stock
    INBX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $245.00
  • Aug 21, 2026
    Stock
    COGT
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $55.00
  • Aug 21, 2026
    Stock
    RLAY
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $29.00
  • Aug 21, 2026
    Stock
    ELTX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $23.00

Robert’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Robert Burns’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Robert Burns ranks #580 of 1,000 with a 4.7★ rating. 21.0% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 34.1% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Robert Burns’s success rate is 40.8% by the ranking source and 21.0% by Exent’s price-target hit-rate backtest, with a median of 106 days to reach a target.

Robert Burns (H.C. Wainwright) covers 49 stocks, mostly in healthcare. The most frequently rated are NUVB, COGT, ZYME, ORIC, NRIX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.